Holly Janes, Ph.D. - Publications

Affiliations: 
2005 University of Washington, Seattle, Seattle, WA 
Area:
Statistics, Public Health

75 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Janes H, Brown MD, Glidden DV, Mayer KH, Buchbinder SP, McMahan VM, Schechter M, Guanira J, Casapia M. Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors. Plos One. 14: e0222183. PMID 31536518 DOI: 10.1371/journal.pone.0222183  0.56
2019 Kerr KF, Brown MD, Marsh TL, Janes H. Assessing the Clinical Impact of Risk Models for Opting Out of Treatment. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X18819479. PMID 30649998 DOI: 10.1177/0272989X18819479  0.56
2017 Janes H, Brown MD, Crager MR, Miller DP, Barlow WE. Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer. Contemporary Clinical Trials. PMID 28818434 DOI: 10.1016/j.cct.2017.08.004  0.56
2017 Huang Y, Zhang L, Janes H, Frahm N, Isaacs A, Kim JH, Montefiori D, McElrath MJ, Tomaras GD, Gilbert PB. Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. Vaccine. PMID 28131393 DOI: 10.1016/j.vaccine.2016.09.053  0.4
2016 Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, Hammer SM, Gilbert PB, Donnell DJ. Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. Journal of Acquired Immune Deficiency Syndromes (1999). 73: 606-608. PMID 27846073 DOI: 10.1097/QAI.0000000000001160  0.4
2016 Gilbert PB, Huang Y, Janes HE. Modeling HIV vaccine trials of the future. Current Opinion in Hiv and Aids. PMID 27662407 DOI: 10.1097/COH.0000000000000314  0.4
2016 Huang Y, Gilbert PB, Fu R, Janes H. Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials. Biostatistics (Oxford, England). PMID 27649715 DOI: 10.1093/biostatistics/kxw043  0.4
2016 Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, Hammer SM, Gilbert PB, Donnell DJ. Preventing HIV-1 Infection in Women using Oral Pre-Exposure Prophylaxis: A Meta-analysis of Current Evidence. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 27552075 DOI: 10.1097/QAI.0000000000001160  1
2016 Kerr KF, Brown MD, Zhu K, Janes H. Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27247223 DOI: 10.1200/JCO.2015.65.5654  0.56
2016 Gilbert PB, Janes HE, Huang Y. Power/sample size calculations for assessing correlates of risk in clinical efficacy trials. Statistics in Medicine. PMID 27037797 DOI: 10.1002/sim.6952  1
2016 Pepe MS, Janes H, Li CI, Bossuyt PM, Feng Z, Hilden J. Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility? Clinical Chemistry. PMID 27001493 DOI: 10.1373/clinchem.2015.252163  1
2016 Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, Kanesa-Thasan N, Bourguignon P, Collard A, Buchbinder S, Tomaras GD, et al. Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Current Opinion in Virology. 17: 57-65. PMID 26827165 DOI: 10.1016/j.coviro.2016.01.007  1
2015 Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, et al. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. Clinical Chemistry. 61: 1446-52. PMID 26510957 DOI: 10.1373/clinchem.2015.246280  0.32
2015 Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J, O'Sullivan MJ, Thorpe J, Robinson RD, Lane D, Li CI, et al. Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. Gynecologic Oncology. PMID 26343159 DOI: 10.1016/j.ygyno.2015.08.024  0.4
2015 Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, et al. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. Plos One. 10: e0136626. PMID 26332672 DOI: 10.1371/journal.pone.0136626  1
2015 Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, et al. HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nature Medicine. PMID 26322580 DOI: 10.1038/nm.3932  1
2015 Janes H, Brown MD, Pepe MS. Designing a study to evaluate the benefit of a biomarker for selecting patient treatment. Statistics in Medicine. PMID 26112650 DOI: 10.1002/sim.6564  1
2015 Janes H, Pepe MS, McShane LM, Sargent DJ, Heagerty PJ. The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. Journal of the National Cancer Institute. 107. PMID 26109106 DOI: 10.1093/jnci/djv157  1
2015 Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, Kublin JG, Corey L, McElrath MJ, Gilbert PB. Use of placebos in Phase 1 preventive HIV vaccine clinical trials. Vaccine. 33: 749-52. PMID 25454855 DOI: 10.1016/j.vaccine.2014.10.017  1
2015 Huang Y, Laber EB, Janes H. Characterizing expected benefits of biomarkers in treatment selection. Biostatistics (Oxford, England). 16: 383-99. PMID 25190512 DOI: 10.1093/biostatistics/kxu039  1
2014 Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, ... Janes H, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. The Journal of Clinical Investigation. 124: 3879-90. PMID 25105367 DOI: 10.1172/JCI75539  1
2014 Kang C, Janes H, Huang Y. Rejoinder: Combining biomarkers to optimize patient treatment recommendations. Biometrics. 70: 719-20. PMID 24889787 DOI: 10.1111/biom.12192  1
2014 Kang C, Janes H, Huang Y. Combining biomarkers to optimize patient treatment recommendations. Biometrics. 70: 695-707. PMID 24889663 DOI: 10.1111/biom.12191  1
2014 Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, Edlefsen PT, Frahm N, Larsen BB, Tovanabutra S, Sanders-Buell E, et al. Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. Journal of Virology. 88: 8242-55. PMID 24829343 DOI: 10.1128/JVI.01164-14  1
2014 Janes H, Brown MD, Huang Y, Pepe MS. An approach to evaluating and comparing biomarkers for patient treatment selection. The International Journal of Biostatistics. 10: 99-121. PMID 24695044 DOI: 10.1515/ijb-2012-0052  1
2014 Pepe MS, Janes H, Li CI. Net risk reclassification p values: valid or misleading? Journal of the National Cancer Institute. 106: dju041. PMID 24681599 DOI: 10.1093/jnci/dju041  1
2014 Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology (Cambridge, Mass.). 25: 114-21. PMID 24240655 DOI: 10.1097/EDE.0000000000000018  1
2014 Janes H, Pepe MS, Huang Y. A framework for evaluating markers used to select patient treatment. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 34: 159-67. PMID 23811760 DOI: 10.1177/0272989X13493147  1
2013 Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM, Wasserheit JN. Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'. Aids (London, England). 27: 2826-7. PMID 24384634 DOI: 10.1097/QAD.0000000000000002  1
2013 Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. The New England Journal of Medicine. 369: 2083-92. PMID 24099601 DOI: 10.1056/NEJMoa1310566  1
2013 Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM, Wasserheit JN. Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? Aids (London, England). 27: 2494-6. PMID 24029738 DOI: 10.1097/01.aids.0000432463.23508.a2  1
2013 Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, Casimiro DR, Carrington M, Geraghty DE, Gilbert PB, McElrath MJ, Frahm N. Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. The Journal of Infectious Diseases. 208: 1231-9. PMID 23878319 DOI: 10.1093/infdis/jit322  1
2013 Moodie Z, Janes H, Huang Y. New clinical trial designs for HIV vaccine evaluation. Current Opinion in Hiv and Aids. 8: 437-42. PMID 23872613 DOI: 10.1097/COH.0b013e328363d46a  1
2013 Janes H. Letter to the editor. Biostatistics (Oxford, England). 14: 807-8. PMID 23624212 DOI: 10.1093/biostatistics/kxt013  1
2013 Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM. In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities. Aids Research and Human Retroviruses. 29: 1513-23. PMID 23597282 DOI: 10.1089/AID.2012.0385  1
2013 Janes H, Pepe M. Re: "Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study". American Journal of Epidemiology. 177: 864-5. PMID 23524037 DOI: 10.1093/aje/kwt043  1
2013 Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM, Wasserheit JN. Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? Aids (London, England). 27: 981-9. PMID 23196933 DOI: 10.1097/QAD.0b013e32835cb927  1
2013 Pepe M, Janes H. Methods for evaluating prediction performance of biomarkers and tests Lecture Notes in Statistics. 215: 107-142. DOI: 10.1007/978-1-4614-8981-8_7  1
2012 Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP, Corey L, Mullins JI, McElrath MJ, Gilbert P. MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. Plos One. 7: e43396. PMID 22952672 DOI: 10.1371/journal.pone.0043396  1
2012 Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, ... ... Janes H, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New England Journal of Medicine. 366: 1275-86. PMID 22475592 DOI: 10.1056/NEJMoa1113425  1
2012 Huang Y, Gilbert PB, Janes H. Assessing treatment-selection markers using a potential outcomes framework. Biometrics. 68: 687-96. PMID 22299708 DOI: 10.1111/j.1541-0420.2011.01722.x  1
2011 Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow R, Fuchs J, Mark KE, Casapia M, Mehrotra DV, Buchbinder SP, Corey L. Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). Journal of Acquired Immune Deficiency Syndromes (1999). 57: 238-44. PMID 21860356 DOI: 10.1097/QAI.0b013e31821acb5  1
2011 Pepe MS, Janes H. Commentary: Reporting standards are needed for evaluations of risk reclassification. International Journal of Epidemiology. 40: 1106-8. PMID 21571811 DOI: 10.1093/ije/dyr083  1
2011 Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Clinical Investigation. 41: 1010-35. PMID 21434890 DOI: 10.1111/j.1365-2362.2011.02493.x  1
2011 Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Epidemiology. 26: 313-37. PMID 21424820 DOI: 10.1007/s10654-011-9551-z  1
2011 Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, et al. Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration. Journal of Clinical Epidemiology. 64: e1-e22. PMID 21414753 DOI: 10.1016/j.jclinepi.2011.02.003  1
2011 Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Human Genetics : Ejhg. 19: 18 p preceding 494. PMID 21407270 DOI: 10.1038/ejhg.2011.27  1
2011 Fitzgerald DW, Janes H, Robertson M, Coombs R, Frank I, Gilbert P, Loufty M, Mehrotra D, Duerr A. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: Results from a randomized placebo-controlled trial (The step study) Journal of Infectious Diseases. 203: 765-772. PMID 21343146 DOI: 10.1093/infdis/jiq114  1
2011 Janes H, Pepe MS, Bossuyt PM, Barlow WE. Measuring the performance of markers for guiding treatment decisions. Annals of Internal Medicine. 154: 253-9. PMID 21320940 DOI: 10.7326/0003-4819-154-4-201102150-00006  1
2010 Janes H, Dominici F, Zeger S. On quantifying the magnitude of confounding. Biostatistics (Oxford, England). 11: 572-82. PMID 20203259 DOI: 10.1093/biostatistics/kxq007  1
2010 Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. Journal of Virology. 84: 1439-52. PMID 19939925 DOI: 10.1128/JVI.02108-09  1
2009 Janes H, Pepe MS. Adjusting for covariate effects on classification accuracy using the covariate-adjusted receiver operating characteristic curve. Biometrika. 96: 371-382. PMID 22822245 DOI: 10.1093/biomet/asp002  1
2009 Pepe M, Longton G, Janes H. Estimation and Comparison of Receiver Operating Characteristic Curves. The Stata Journal. 9: 1. PMID 20161343  1
2009 Janes H, Longton G, Pepe M. Accommodating Covariates in ROC Analysis. The Stata Journal. 9: 17-39. PMID 20046933  0.56
2009 Janes H, Longton G, Pepe MS. Accommodating covariates in receiver operating characteristic analysis Stata Journal. 9: 17-39.  1
2009 Janes H, Pepe MS, Gu W. In response Annals of Internal Medicine. 150: 428.  1
2008 Janes H, Pepe MS, Gu W. Assessing the value of risk predictions by using risk stratification tables. Annals of Internal Medicine. 149: 751-60. PMID 19017593  1
2008 McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (London, England). 372: 1894-905. PMID 19012957 DOI: 10.1016/S0140-6736(08)61592-5  1
2008 Janes H, Sheppard L, Shepherd K. Statistical analysis of air pollution panel studies: an illustration. Annals of Epidemiology. 18: 792-802. PMID 18922395 DOI: 10.1016/j.annepidem.2008.06.004  1
2008 Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. Journal of the National Cancer Institute. 100: 1432-8. PMID 18840817 DOI: 10.1093/jnci/djn326  1
2008 Pepe MS, Janes HE. Gauging the performance of SNPs, biomarkers, and clinical factors for predicting risk of breast cancer. Journal of the National Cancer Institute. 100: 978-9. PMID 18612128 DOI: 10.1093/jnci/djn215  1
2008 Janes H, Pepe MS. Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting. American Journal of Epidemiology. 168: 89-97. PMID 18477651 DOI: 10.1093/aje/kwn099  1
2008 Eftim SE, Samet JM, Janes H, McDermott A, Dominici F. Fine particulate matter and mortality: a comparison of the six cities and American Cancer Society cohorts with a medicare cohort. Epidemiology (Cambridge, Mass.). 19: 209-16. PMID 18223484 DOI: 10.1097/EDE.0b013e3181632c09  1
2008 Janes H, Pepe MS. Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value. Biometrics. 64: 1-9. PMID 17501939 DOI: 10.1111/j.1541-0420.2007.00823.x  1
2007 Pepe MS, Janes H, Gu JW. Letter by Pepe et al regarding article, "Use and misuse of the receiver operating characteristic curve in risk prediction". Circulation. 116: e132; author reply e. PMID 17679623 DOI: 10.1161/CIRCULATIONAHA.107.709253  1
2007 Janes H, Dominici F, Zeger SL. Trends in air pollution and mortality: an approach to the assessment of unmeasured confounding. Epidemiology (Cambridge, Mass.). 18: 416-23. PMID 17568215 DOI: 10.1097/EDE.0b013e31806462e9  1
2007 Pepe MS, Janes H. Insights into latent class analysis of diagnostic test performance. Biostatistics (Oxford, England). 8: 474-84. PMID 17085745 DOI: 10.1093/biostatistics/kxl038  1
2007 Janes H, Dominici F, Zeger S. Partitioning evidence of association between air pollution and mortality Epidemiology. 18: 427-428. DOI: 10.1097/EDE.0b013e318068647b  1
2006 Lumley T, Janes H, Sheppard L. Cox models for ecologic time-series data? Environmental Health Perspectives. 114: A690-1; author reply. PMID 17185253  1
2006 Janes H, Pepe M. The optimal ratio of cases to controls for estimating the classification accuracy of a biomarker. Biostatistics (Oxford, England). 7: 456-68. PMID 16428259 DOI: 10.1093/biostatistics/kxj018  1
2005 Janes H, Sheppard L, Lumley T. Case-crossover analyses of air pollution exposure data: referent selection strategies and their implications for bias. Epidemiology (Cambridge, Mass.). 16: 717-26. PMID 16222160 DOI: 10.1097/01.ede.0000181315.18836.9d  1
2005 Janes H, Sheppard L, Lumley T. Do subject characteristics modify the effects of particulate air pollution on daily mortality among the elderly? Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 47: 543; author reply 54. PMID 15951711 DOI: 10.1097/01.jom.0000163606.63666.9e  1
2005 Janes H, Pepe M, Kooperberg C, Newcomb P. Identifying target populations for screening or not screening using logic regression. Statistics in Medicine. 24: 1321-38. PMID 15568185 DOI: 10.1002/sim.2021  1
2005 Janes H, Sheppard L, Lumley T. Overlap bias in the case-crossover design, with application to air pollution exposures. Statistics in Medicine. 24: 285-300. PMID 15546133 DOI: 10.1002/sim.1889  1
2004 Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. American Journal of Epidemiology. 159: 882-90. PMID 15105181 DOI: 10.1093/aje/kwh101  1
Show low-probability matches.